Predictiv AI Announces Sale Of 34 ThermalPass Devices

Predictiv AI (TSXV: PAI) continues to see orders flow in for its ThermalPass fever detection system. The company this morning provided a further update on the sales exhibited by the sensor based screening system, with the announcement of an additional 34 units being sold.

The 34 units have been sold since the company’s previous announcement related to sales in early December. The additional units were reportedly sold to aboriginal communities, prisons, hospitals and public schools across both Canada and the US. The company is currently focusing on sales expansion across a number of sectors, including retail, professional sports, cruise lines, manufacturers, and a number of corporations.

Total sales figures have hit 62 devices as of the latest update, with the devices being officially on the market for a period of seven weeks. While early stage figures, the company has referred to these sales as being “foundational,” stating, “we see strong potential to receive large batch orders from these same customers in Q1 2021 and beyond.”

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Predictiv AI last traded at $0.18 on the TSX Venture.


FULL DISCLOSURE: Predictiv AI Inc is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Predictiv AI Inc on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

The Gold & Copper Stocks Everyone Keeps Asking About | Oct. 12-16 – Weekly Mining Mailbag

Similar Gold Mines Are Valued 10X Higher. Why Not This One? | JW Dumont – Granada Gold Mine

The US Interest Bill Gold Can’t Ignore | Peter Grandich

Recommended

Cambria’s Silver Coin Infill Program Delivers 98.56 g/t Gold Over 8.2 Metres

First Majestic Produces 3.4 Million Ounces of Silver in Q3 2026, Jerritt Canyon Restart Remains on Track

Related News

Medicago, GSK Report 71% Efficacy Rate From Plant-Based COVID-19 Vaccine Study

Quebec-based biopharmaceutical firm Medicago and healthcare conglomerate GlaxoSmithKline (NYSE: GSK) announce today the results from...

Tuesday, December 7, 2021, 11:21:00 AM

Revive Selects Clinical Sites for FDA Phase 3 Clinical Trials

This morning Revive Therapeutics Ltd (CSE: RVV, OTV: RVVTF), announced they have selected five clinical...

Tuesday, September 29, 2020, 09:45:22 AM

Auditor General Cites $27.4 Billion COVID Benefit Payments Still Unverified, $4.6 Billion Overpayments To Ineligible Recipients

The report also noted the successful speed in obtaining and distributing COVID-19 vaccines but millions...

Wednesday, December 7, 2022, 07:56:44 AM

IEA Cuts Global Oil Demand Forecast as Renewed Lockdowns Limit Mobility

The International Energy Agency (IEA) has revised its 2021 oil forecast, cutting oil demand by...

Saturday, January 23, 2021, 04:26:00 PM

Kyle Bass: China’s Covid-19 Policies Are All Part of Xi’s Plan to Reunify China

Appearing on podcast Forward Guidance last week, Hayman Capital founder Kyle Bass gives his take...

Monday, December 26, 2022, 01:33:00 PM